Skip to content
  • Insights
    • All Insights
    • 2024 Year in Review
    • Pα+ Dashboard
  • Data
    • Psychedelic Company Financing Tracker
    • Psychedelic Drug Development Tracker
    • Worldwide Psychedelic Laws
    • U.S. Psychedelic Policy Reform
    • Psychedelic Patent Trackers
    • Psychedelic Stocks & Companies
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+ Content
  • Pα+ Sign in
Menu
  • Insights
    • All Insights
    • 2024 Year in Review
    • Pα+ Dashboard
  • Data
    • Psychedelic Company Financing Tracker
    • Psychedelic Drug Development Tracker
    • Worldwide Psychedelic Laws
    • U.S. Psychedelic Policy Reform
    • Psychedelic Patent Trackers
    • Psychedelic Stocks & Companies
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+ Content
  • Pα+ Sign in
Subscribe
Search
Close this search box.
Read more about the article Numinus Wellness Commends Health Canada on Special Access Programme Amendments to Restore Potential Access to Psychedelic Medicines

Numinus Wellness Commends Health Canada on Special Access Programme Amendments to Restore Potential Access to Psychedelic Medicines

  • Post published:December 22, 2021
  • Post category:Press Release
Read more about the article Numinus Wellness Inc. to Commence Trading on the TSX on December 16, 2021

Numinus Wellness Inc. to Commence Trading on the TSX on December 16, 2021

  • Post published:December 14, 2021
  • Post category:Press Release
Read more about the article Numinus Wellness Inc. Reports Q4 and Year End 2021 Results

Numinus Wellness Inc. Reports Q4 and Year End 2021 Results

  • Post published:December 9, 2021
  • Post category:Press Release
Read more about the article Numinus Develops Proprietary Psychedelic Tests with New Toxicity and Potency Scans

Numinus Develops Proprietary Psychedelic Tests with New Toxicity and Potency Scans

  • Post published:November 29, 2021
  • Post category:Press Release
Read more about the article Numinus Receives Conditional Approval to Graduate to the Toronto Stock Exchange

Numinus Receives Conditional Approval to Graduate to the Toronto Stock Exchange

  • Post published:November 26, 2021
  • Post category:Press Release
Read more about the article Numinus Announces Departure of Stacey Wallin

Numinus Announces Departure of Stacey Wallin

  • Post published:November 25, 2021
  • Post category:Press Release
Read more about the article Numinus to Host Q4 and 2021 Annual Results Conference Call on December 9, 2021

Numinus to Host Q4 and 2021 Annual Results Conference Call on December 9, 2021

  • Post published:November 22, 2021
  • Post category:Press Release
Read more about the article Numinus to Begin Trading on the OTC Under Symbol NUMIF

Numinus to Begin Trading on the OTC Under Symbol NUMIF

  • Post published:November 19, 2021
  • Post category:Press Release
Read more about the article Numinus to Host Extension of MAPS-Sponsored MDMA-Assisted Therapy for PTSD Trials

Numinus to Host Extension of MAPS-Sponsored MDMA-Assisted Therapy for PTSD Trials

  • Post published:November 10, 2021
  • Post category:Press Release
Read more about the article Numinus Advances Phase 1 Trial on Proprietary Psilocybin Product

Numinus Advances Phase 1 Trial on Proprietary Psilocybin Product

  • Post published:October 20, 2021
  • Post category:Press Release

End of content

No more pages to load

← Newer Posts
Older Posts →

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

  • Insights
  • Jobs
  • Data
  • Subscribe to Pα+
  • Contact

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.

Subscribe to Pα+
  • Psychedelic Alpha © 2025, All Rights Reserved
  • Privacy Policy
  • Terms of Service

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights

Subscribe Annually ($200)
Subscribe Monthly ($20)
Learn More